Data Insights

Irinotecan hydrochloride by Les Laboratoires Servier for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Les Laboratoires Servier and currently in Phase II for Esophageal Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Esophageal Squamous Cell Carcinoma (ESCC)

Data Insights

Irinotecan hydrochloride by Ipsen for Extrahepatic Bile Duct Cancer: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Extrahepatic Bile Duct Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Extrahepatic Bile Duct Cancer

Data Insights

Irinotecan hydrochloride by Ipsen for Metastatic Biliary Tract Cancer: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Metastatic Biliary Tract Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Metastatic Biliary Tract Cancer

Data Insights

Irinotecan hydrochloride by Ipsen for Gastric Cancer: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Gastric Cancer. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Gastric Cancer

Data Insights

Irinotecan hydrochloride by CSPC Pharmaceutical Group for Ewing Sarcoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Ewing Sarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Ewing Sarcoma

Data Insights

Irinotecan hydrochloride by Ipsen for Solid Tumor: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Solid Tumor. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Solid Tumor

Data Insights

Irinotecan hydrochloride by CSPC Pharmaceutical Group for Metastatic Colorectal Cancer: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Phase I for Metastatic Colorectal Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Metastatic Colorectal Cancer

Data Insights

Irinotecan hydrochloride by CSPC Pharmaceutical Group for Metastatic Pancreatic Cancer: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by CSPC Pharmaceutical Group and currently in Pre-Registration for Metastatic Pancreatic Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Metastatic Pancreatic Cancer

Data Insights

Irinotecan hydrochloride by Ipsen for Neuroendocrine Carcinoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Neuroendocrine Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Neuroendocrine Carcinoma

Data Insights

Irinotecan hydrochloride by Ipsen for Epithelial Ovarian Cancer: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase II for Epithelial Ovarian Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Epithelial Ovarian Cancer

Data Insights

Irinotecan hydrochloride by Ipsen for Rhabdomyosarcoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Rhabdomyosarcoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Rhabdomyosarcoma

Data Insights

Irinotecan hydrochloride by Ipsen for Neuroblastoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Neuroblastoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Neuroblastoma

Data Insights

Irinotecan hydrochloride by Ipsen for Ewing Sarcoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Ewing Sarcoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Ewing Sarcoma

Data Insights

Irinotecan hydrochloride by Ipsen for Osteosarcoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Ipsen and currently in Phase I for Osteosarcoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Osteosarcoma

Data Insights

Irinotecan hydrochloride by Edison Oncology Holding for Hepatic (Liver) Tumor: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Hepatic (Liver) Tumor. According...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Hepatic (Liver) Tumor

Data Insights

Irinotecan hydrochloride by Edison Oncology Holding for Ewing Sarcoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Ewing Sarcoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Ewing Sarcoma

Data Insights

Irinotecan hydrochloride by Edison Oncology Holding for Medulloblastoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Medulloblastoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Medulloblastoma

Data Insights

Irinotecan hydrochloride by Edison Oncology Holding for Neuroblastoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Neuroblastoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Neuroblastoma

Data Insights

Irinotecan hydrochloride by Edison Oncology Holding for Rhabdomyosarcoma: Likelihood of Approval

Irinotecan hydrochloride is under clinical development by Edison Oncology Holding and currently in Phase II for Rhabdomyosarcoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Irinotecan Hydrochloride in Rhabdomyosarcoma